{
    "2019-09-05": [
        [
            {
                "time": "2018-06-04",
                "original_text": "AstraZeneca's Tagrisso Gets Nod in China for First-Line NSCLC",
                "features": {
                    "keywords": [
                        "AstraZeneca",
                        "Tagrisso",
                        "China",
                        "First-Line",
                        "NSCLC"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            },
            {
                "time": "2018-06-04",
                "original_text": "Notable Thursday Option Activity: BLK, LLY, ABMD",
                "features": {
                    "keywords": [
                        "Option Activity",
                        "BLK",
                        "LLY",
                        "ABMD"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "financial services",
                        "healthcare"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "none",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-06-04",
                "original_text": "Lilly's Pain Clinical Trial Protocol Selected for FDA Complex Innovative Trial Designs Pilot Meeting Program",
                "features": {
                    "keywords": [
                        "Lilly",
                        "Pain",
                        "Clinical Trial",
                        "FDA",
                        "Complex Innovative Trial Designs",
                        "Pilot Meeting Program"
                    ],
                    "sentiment_score": 0.85,
                    "policy_related": "true",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            },
            {
                "time": "2018-06-04",
                "original_text": "Is the FDA Out to Get This $2.9 Billion Diabetes Drug Class?",
                "features": {
                    "keywords": [
                        "FDA",
                        "Diabetes",
                        "Drug Class"
                    ],
                    "sentiment_score": -0.6,
                    "policy_related": "true",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            },
            {
                "time": "2018-06-04",
                "original_text": "J&J's Stelara Gets Approval in EU for Ulcerative Colitis",
                "features": {
                    "keywords": [
                        "J&J",
                        "Stelara",
                        "Approval",
                        "EU",
                        "Ulcerative Colitis"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            },
            {
                "time": "2018-06-04",
                "original_text": "Calculating The Fair Value Of Eli Lilly and Company (NYSE:LLY)",
                "features": {
                    "keywords": [
                        "Fair Value",
                        "Eli Lilly",
                        "LLY"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "none",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}